Pharma&Biotech Overview

Lonza’s Pharma&Biotech vision is to enable our customers to meet some of the greatest challenges in patient treatment. The Pharma&Biotech market-focused segment is comprised of the following businesses:

Pharma&Biotech Overview 2016

Our Pharma&Biotech segment delivered remarkable sales growth of 15.9% (15.8% in constant exchange rates), reaching CHF 1.85 billion, which led to an exceptional CORE EBIT of CHF 400 million and an extremely high 40.8% CORE EBIT growth year-over-year.

This outstanding performance was driven by commercial excellence and strong operational execution. The strong momentum in Mammalian Manufacturing was complemented by a significant upward trend in all other technologies and modalities. Furthermore, our continued cost and manufacturing discipline helped the segment achieve these remarkable results. Our strong regulatory track record continued with 154 successful regulatory and customer audits.

During 2016 Lonza’s Pharma&Biotech segment announced several long-term, strategic manufacturing agreements, such as with Kodiak Sciences, bluebird bio and Clovis Oncology.

In the year ahead, Lonza’s Pharma&Biotech will focus on strengthening our core offering to deliver further operational and commercial excellence.

Pharma&Biotech Financial Summary 

million CHF 2016 Change in % 2015
       
Sales 1,849 15.9 1,596
CORE EBIT1 400 40.8 284
CORE EBIT margin in % 21.6   17.8
CORE EBITDA1 531 27.0 418
CORE EBITDA margin in % 28.7   26.2